Literature DB >> 19447886

Catalytic activity and inhibition of wegener antigen proteinase 3 on the cell surface of human polymorphonuclear neutrophils.

Brice Korkmaz1, Jérôme Jaillet, Marie-Lise Jourdan, Alexandre Gauthier, Francis Gauthier, Sylvie Attucci.   

Abstract

Proteinase 3 (Pr3), the main target of anti-neutrophil cytoplasmic antibodies, is a neutrophil serine protease that may be constitutively expressed at the surface of quiescent circulating neutrophils. This raises the question of the simultaneous presence in the circulation of constitutive membrane-bound Pr3 (mPr3) and its plasma inhibitor alpha1-protease inhibitor (alpha1-Pi). We have looked at the fate of constitutive mPr3 at the surface of circulating blood neutrophils and of induced mPr3 on triggered neutrophils. We found significant Pr3 activity at the surface of activated neutrophils but not at the surface of quiescent neutrophils whatever the constitutive expression. This suggests that constitutive mPr3 is enzymatically inactive or its active site is not accessible to the substrate. Supporting this conclusion, we have not been able to demonstrate any interaction between constitutive mPr3 and alpha1-Pi, whereas induced mPr3 is cleared from the cell surface when activated cells are incubated with this inhibitor. But, unlike membrane-bound elastase that is also cleared from the surface of activated cells, mPr3 remained bound to the membrane when inhibited by elafin or by a low molecular weight chloromethyl ketone inhibitor, which shows that it binds more tightly to the neutrophil membrane. mPr3 may thus be present at the surface of circulating neutrophils in an environment replete with alpha1-Pi. The permanent presence of inactive Pr3 at the surface of quiescent neutrophils may explain why Pr3 is a major target of anti-neutrophil cytoplasmic antibodies, whose binding activates neutrophils and triggers inflammation, as in Wegener granulomatosis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19447886      PMCID: PMC2740415          DOI: 10.1074/jbc.M901471200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  43 in total

Review 1.  Elastolytic proteases: inflammation resolution and dysregulation in chronic infective lung disease.

Authors:  Clifford C Taggart; Catherine M Greene; Tomas P Carroll; Shane J O'Neill; Noel G McElvaney
Journal:  Am J Respir Crit Care Med       Date:  2005-02-01       Impact factor: 21.405

2.  Presence of proteinase 3 in secretory vesicles: evidence of a novel, highly mobilizable intracellular pool distinct from azurophil granules.

Authors:  V Witko-Sarsat; E M Cramer; C Hieblot; J Guichard; P Nusbaum; S Lopez; P Lesavre; L Halbwachs-Mecarelli
Journal:  Blood       Date:  1999-10-01       Impact factor: 22.113

3.  Ultrastructural localization of proteinase 3, the target antigen of anti-cytoplasmic antibodies circulating in Wegener's granulomatosis.

Authors:  E Csernok; J Lüdemann; W L Gross; D F Bainton
Journal:  Am J Pathol       Date:  1990-11       Impact factor: 4.307

4.  Competition between elastase and related proteases from human neutrophil for binding to alpha1-protease inhibitor.

Authors:  Brice Korkmaz; Pierre Poutrain; Eric Hazouard; Michèle de Monte; Sylvie Attucci; Francis L Gauthier
Journal:  Am J Respir Cell Mol Biol       Date:  2005-03-11       Impact factor: 6.914

5.  A large subset of neutrophils expressing membrane proteinase 3 is a risk factor for vasculitis and rheumatoid arthritis.

Authors:  V Witko-Sarsat; P Lesavre; S Lopez; G Bessou; C Hieblot; B Prum; L H Noël; L Guillevin; P Ravaud; I Sermet-Gaudelus; J Timsit; J P Grünfeld; L Halbwachs-Mecarelli
Journal:  J Am Soc Nephrol       Date:  1999-06       Impact factor: 10.121

6.  In situ localization by double-labeling immunoelectron microscopy of anti-neutrophil cytoplasmic autoantibodies in neutrophils and monocytes.

Authors:  J Calafat; R Goldschmeding; P L Ringeling; H Janssen; C E van der Schoot
Journal:  Blood       Date:  1990-01-01       Impact factor: 22.113

7.  Interaction of purified human proteinase 3 (PR3) with reconstituted lipid bilayers.

Authors:  W H Goldmann; J L Niles; M A Arnaout
Journal:  Eur J Biochem       Date:  1999-04

8.  Constitutive membrane expression of proteinase 3 (PR3) and neutrophil activation by anti-PR3 antibodies.

Authors:  André P van Rossum; Agnieszka A Rarok; Minke G Huitema; Giorgio Fassina; Pieter C Limburg; Cees G M Kallenberg
Journal:  J Leukoc Biol       Date:  2004-08-26       Impact factor: 4.962

9.  Bimodal distribution of proteinase 3 (PR3) surface expression reflects a constitutive heterogeneity in the polymorphonuclear neutrophil pool.

Authors:  L Halbwachs-Mecarelli; G Bessou; P Lesavre; S Lopez; V Witko-Sarsat
Journal:  FEBS Lett       Date:  1995-10-23       Impact factor: 4.124

10.  A secreted proform of neutrophil proteinase 3 regulates the proliferation of granulopoietic progenitor cells.

Authors:  S Sköld; B Rosberg; U Gullberg; T Olofsson
Journal:  Blood       Date:  1999-02-01       Impact factor: 22.113

View more
  11 in total

Review 1.  Neutrophil elastase, proteinase 3, and cathepsin G as therapeutic targets in human diseases.

Authors:  Brice Korkmaz; Marshall S Horwitz; Dieter E Jenne; Francis Gauthier
Journal:  Pharmacol Rev       Date:  2010-12       Impact factor: 25.468

2.  Interaction of serine proteases from polymorphonuclear leucocytes with the cell surface and heparin.

Authors:  Jana Fleddermann; Annelie Pichert; Jürgen Arnhold
Journal:  Inflammation       Date:  2012-02       Impact factor: 4.092

Review 3.  Changes in Pulmonary Microenvironment Aids Lung Metastasis of Breast Cancer.

Authors:  Meimei Wu; Yanfang Liang; Xin Zhang
Journal:  Front Oncol       Date:  2022-05-26       Impact factor: 5.738

Review 4.  Neutrophil proteinase 3 and dipeptidyl peptidase I (cathepsin C) as pharmacological targets in granulomatosis with polyangiitis (Wegener granulomatosis).

Authors:  Brice Korkmaz; Adam Lesner; Stephanie Letast; Yassir K Mahdi; Marie-Lise Jourdan; Sandrine Dallet-Choisy; Sylvain Marchand-Adam; Christine Kellenberger; Marie-Claude Viaud-Massuard; Dieter E Jenne; Francis Gauthier
Journal:  Semin Immunopathol       Date:  2013-02-06       Impact factor: 9.623

5.  New selective peptidyl di(chlorophenyl) phosphonate esters for visualizing and blocking neutrophil proteinase 3 in human diseases.

Authors:  Carla Guarino; Monika Legowska; Christophe Epinette; Christine Kellenberger; Sandrine Dallet-Choisy; Marcin Sieńczyk; Guillaume Gabant; Martine Cadene; Jérôme Zoidakis; Antonia Vlahou; Magdalena Wysocka; Sylvain Marchand-Adam; Dieter E Jenne; Adam Lesner; Francis Gauthier; Brice Korkmaz
Journal:  J Biol Chem       Date:  2014-10-06       Impact factor: 5.157

6.  α-1-antitrypsin variants and the proteinase/antiproteinase imbalance in chronic obstructive pulmonary disease.

Authors:  Nicola J Sinden; Michael J Baker; David J Smith; Jan-Ulrich Kreft; Timothy R Dafforn; Robert A Stockley
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2015-01-15       Impact factor: 5.464

7.  Characterization of the CD177 interaction with the ANCA antigen proteinase 3.

Authors:  Uwe Jerke; Stephen F Marino; Oliver Daumke; Ralph Kettritz
Journal:  Sci Rep       Date:  2017-02-27       Impact factor: 4.379

Review 8.  The Multifaceted Effects of Alpha1-Antitrypsin on Neutrophil Functions.

Authors:  Sabina Janciauskiene; Sabine Wrenger; Stephan Immenschuh; Beata Olejnicka; Timm Greulich; Tobias Welte; Joanna Chorostowska-Wynimko
Journal:  Front Pharmacol       Date:  2018-04-17       Impact factor: 5.810

Review 9.  Proteinase 3; a potential target in chronic obstructive pulmonary disease and other chronic inflammatory diseases.

Authors:  Helena Crisford; Elizabeth Sapey; Robert A Stockley
Journal:  Respir Res       Date:  2018-09-20

10.  The pig as a model for investigating the role of neutrophil serine proteases in human inflammatory lung diseases.

Authors:  Déborah Bréa; François Meurens; Alice V Dubois; Julien Gaillard; Claire Chevaleyre; Marie-Lise Jourdan; Nathalie Winter; Brigitte Arbeille; Mustapha Si-Tahar; Francis Gauthier; Sylvie Attucci
Journal:  Biochem J       Date:  2012-11-01       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.